Eventide Asset Management, LLC Xenon Pharmaceuticals Inc. Transaction History

Eventide Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	SELL	$34.84 - $43.54 $7.92 Million - $9.9 Million	-227,294 Reduced 35.45%	413,906 $15.9 Million
Q3 2022 Nov 14, 2022	BUY	$30.79 - $39.82 $5.28 Million - $6.83 Million	171,500 Added 36.51%	641,200 $23.1 Million
Q2 2022 Aug 15, 2022	BUY	$25.44 - $35.16 $11.9 Million - $16.5 Million	469,700 New	469,700 $14.3 Million
Q3 2021 Nov 15, 2021	SELL	$14.86 - $19.45 $22.1 Million - $29 Million	-1,490,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$13.65 - $21.31 $6.28 Million - $9.8 Million	459,860 Added 44.64%	1,490,000 $26.7 Million
Q4 2020 Feb 16, 2021	SELL	$9.49 - $16.04 $2.32 Million - $3.91 Million	-243,960 Reduced 19.15%	1,030,140 $15.8 Million
Q2 2019 Aug 14, 2019	BUY	$8.51 - $10.75 $5.56 Million - $7.02 Million	653,409 Added 105.27%	1,274,100 $12.6 Million
Q1 2019 May 15, 2019	BUY	$6.39 - $10.42 $1.25 Million - $2.05 Million	196,258 Added 46.24%	620,691 $6.31 Million
Q4 2018 Feb 14, 2019	BUY	$5.61 - $12.62 $613,919 - $1.38 Million	109,433 Added 34.74%	424,433 $2.68 Million
Q3 2018 Nov 14, 2018	BUY	$9.0 - $14.9 $2.84 Million - $4.69 Million	315,000 New	315,000 $4.16 Million

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.42B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.